Key Players in the South Korea Peripheral Neuropathy Market | Top Companies 2026

Key Players in the South Korea Peripheral Neuropathy Market

The South Korea Peripheral Neuropathy Market is experiencing rapid growth, owing to the longstanding presence of local pharmaceutical giants and global organizations. Major players in the market include SK Biopharmaceuticals, GC Biopharma, Pfizer Korea, and Viatris Korea.

South Korea Peripheral Neuropathy Market Overview

According to 6Wresearch, the South Korea Peripheral Neuropathy Market is poised for significant expansion, driven by a rapidly aging society and an increasing prevalence of metabolic syndromes. The rising cases of diabetic peripheral neuropathy is boosting the demand for a diverse range of pharmacological interventions. Furthermore, improved healthcare infrastructure, along with consumer awareness about nerve health is strengthening the innovation of advanced therapies, including non-invasive nerve stimulation and next-generation pain management solutions.

Competitive Landscape

The competitive landscape of the South Korea peripheral neuropathy industry is defined by continuous investment in biotechnology and strategic global partnerships. Leading brands are focused on innovating novel drug delivery systems and biologics. The market is highly competitive as key players strive to offer a comprehensive portfolio that spans from nerve supplements to advanced prescription-grade anaesthetics.

Below is a list of leading players operating in the South Korea Peripheral Neuropathy Market:

1. Viatris Korea

Viatris is a dominant leader in the pain management space, providing Lyrica, which is essential for treating neuropathic pain in diabetic patients.

2. Pfizer Korea

Pfizer maintains a strong presence with its established legacy portfolio, focusing on clinical advancements and localized post-marketing surveillance.

3. Yuhan Corporation

Yuhan is a local powerhouse known for its R&D in sustained-release technologies, offering high-quality pregabalin formulations that improve patient compliance.

4. Daewoong Pharmaceutical

Daewoong contributes to the market with a robust portfolio of neuroprotective agents and localized treatments for symptoms related to nerve damage.

5. Hanmi Pharmaceutical

Hanmi Pharmaceutical specializes in combination therapies and advanced drug delivery systems that address various chronic neuropathic conditions.

6. GC Biopharma (Green Cross)

GC Biopharma focuses on innovative biological treatments and supportive over-the-counter nerve health solutions that cater to the aging population.

7. SK Biopharmaceuticals

SK Biopharmaceuticals is a leader in CNS research, developing next-generation therapies for neurological disorders and pain management.

8. Boryung

Boryung contributes to the market with its established portfolio of metabolic disease medications, which manage the underlying causes of diabetic neuropathy.

9. Eisai Korea

Eisai Korea is highly specialized in neurology, providing Methycobal for the treatment of peripheral neuropathies.

10. Takeda Korea

Takeda Korea provides specialized treatments for underlying metabolic and inflammatory pathways that contribute to severe peripheral nerve complications.

Key Players in the South Korea Peripheral Neuropathy Market: FAQs